The pharma-biotech executive jumps show no sign of abating as a former Pfizer vet joins the ranks of startup Outpost Medicine as its R&D trials lead.
Ian Mills, M.D., becomes its new chief medical officer, coming from his role as head of clinical development at Mitsubishi Tanabe Pharma Europe; before this, he was a long-serving Pfizer vet serving across several research posts, with a focus on urology.
Outpost, with bases in Indianapolis and London, launched just last year and has since raised $61 million in a series A from the likes of Frazier Healthcare Partners, Adams Street Partners, Novo Holdings, Vivo Capital and Takeda Venture.
When it launched, Takeda gave out an exclusive license to the early-stage biotech for a clinical-stage product candidate in testing for stress urinary incontinence.
“Ian will be an outstanding addition to our leadership team, and we are very pleased to welcome him to Outpost,” said Scott Byrd, CEO of Outpost and formerly of Acacia Pharma and Lilly, in a release. “His extensive global drug development experience, including successfully guiding two pharmaceutical products to FDA approval for urology indications, will be pivotal to building our capabilities and leading the development of our lead product candidate, OP-687, for the treatment of overactive bladder and irritable bowel syndrome.”
By Ben Adams
Source: Fierce Biotech
Monday, the French pharma giant officially moved into its new global home base in Paris, dubbed La Maison Sanofi. The 9,000-square-meter (about 96,875-square-foot) facility comprises two historic buildings and will host around 500 employees, the company explained in a release.
On the first day of the new year, former Sandoz chief Richard Francis will take the reins from Schultz, who is hanging up his CEO hat to retire on Dec. 31, Teva said Monday. The news comes a little more than two weeks after Teva publicly said it was looking for Schultz’s replacement.
General Electric Co. set the terms for the spinoff of its healthcare division, putting an initial value of roughly $31 billion on the soon-to-be-public company. The Boston conglomerate plans to split into three separate public companies by early 2024. Following the healthcare spinoff, it plans to separate its aerospace business from its power and renewable-energy units.